The significance and predictive value of free light chains in the urine of patients with chronic inflammatory rheumatic disease

Clinical Rheumatology

Volumn 35, Issue 12, 2016, Pages 2939-2946

  Bramlage, Carsten Paul ^a,b   Froelich, Britta ^a   Wallbach, Manuel ^a   Minguet, Joan ^b   Grupp, Clemens ^c   Deutsch, Cornelia ^b   Bramlage, Peter ^b   Koziolek, Michael ^a   Müller, Gerhard Anton ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b INSTITUTE FOR PHARMACOLOGY AND PREVENTIVE MEDICINE   (Germany)

^c Hospital of Bamberg   (Germany)

Author keywords

Autoimmune; C reactive protein; Erythrocyte sedimentation rate; Free light chains; Inflammation; Rheumatic disease; Rituximab

Indexed keywords

C REACTIVE PROTEIN; RITUXIMAB; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN;

ADULT; ARTICLE; CONNECTIVE TISSUE DISEASE; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FREE LIGHT CHAIN; GERMANY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KIDNEY FUNCTION; LIGHT CHAIN; MAJOR CLINICAL STUDY; MALE; MYELOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SPONDYLARTHRITIS; UNIVERSITY HOSPITAL; URINE; URINE LEVEL; VASCULITIS; AGED; CHEMISTRY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; RHEUMATIC DISEASES;

ADULT; AGED; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; FEMALE; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; INFLAMMATION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RHEUMATIC DISEASES; RITUXIMAB;

EID: 84991066575     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-016-3437-0     Document Type: Article

References (25)

1. Aggarwal R (2013) Urinary free light chains: a potential biomarker in lupus nephritis. Rheumatology (Oxford) 52:2106–2107
2. Aggarwal R, Sequeira W, Kokebie R, Mikolaitis RA, Fogg L, Finnegan A, Plaas A, Block JA, Jolly M (2011) Serum free light chains as biomarkers for systemic lupus erythematosus disease activity. Arthritis Care Res (Hoboken) 63:891–898
3. Bradwell AR (2005) Serum free light chain measurements move to center stage. Clin Chem 51:805–807
4. Brebner JA, Stockley RA (2013) Polyclonal free light chains: a biomarker of inflammatory disease or treatment target? F1000 Med Rep 5:4
5. Brouwer J, Otting-van de Ruit M, Busking-van der Lely H (1985) Estimation of free light chains of immunoglobulins by enzyme immunoassay. Clin Chim Acta 150:267–274
6. Carubbi F, Alunno A, Cipriani P, Bartoloni E, Ciccia F, Triolo G, Gerli R, Giacomelli R (2014) Rituximab in primary Sjogren’s syndrome: a ten-year journey. Lupus 23:1337–1349
7. Chiche L, Cournac JM, Mancini J, Bardin N, Thomas G, Jean R, Schleinitz N, Kaplanski G, Durand JM, Boucraut J, Harle JR (2011) Normalization of serum-free light chains in patients with systemic lupus erythematosus upon rituximab treatment and correlation with biological disease activity. Clin Rheumatol 30:685–689
8. Draborg AH, Lydolph MC, Westergaard M, Olesen Larsen S, Nielsen CT, Duus K, Jacobsen S, Houen G (2015) Elevated concentrations of serum immunoglobulin free light chains in systemic lupus erythematosus patients in relation to disease activity, inflammatory status, B cell activity and Epstein-Barr Virus antibodies. PLoS One 10:e0138753
9. Gottenberg JE, Aucouturier F, Goetz J, Sordet C, Jahn I, Busson M, Cayuela JM, Sibilia J, Mariette X (2007) Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren’s syndrome. Ann Rheum Dis 66:23–27
10. Gottenberg JE, Miceli-Richard C, Ducot B, Goupille P, Combe B, Mariette X (2009) Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort. Arthritis Res Ther 11:R114
11. Hanaoka M, Gono T, Kawaguchi Y, Uchida K, Koseki Y, Katsumata Y, Kaneko H, Takagi K, Ichida H, Nitta K, Yamanaka H (2013) Urinary free light chain is a potential biomarker for ISN/RPS class III/IV lupus nephritis. Rheumatology (Oxford) 52:2149–2157
12. Hopper JE, Golbus J, Meyer C, Ferrer GA (2000) Urine free light chains in SLE: clonal markers of B-cell activity and potential link to in vivo secreted Ig. J Clin Immunol 20:123–137
13. Hutchison CA, Harding S, Hewins P, Mead GP, Townsend J, Bradwell AR, Cockwell P (2008) Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol 3:1684–1690
14. Hutchison CA, Landgren O (2011) Polyclonal immunoglobulin free light chains as a potential biomarker of immune stimulation and inflammation. Clin Chem 57:1387–1389
15. Jolly M, Francis S, Aggarwal R, Mikolaitis RA, Niewold TB, Chubinskaya S, Block JA, Scanzello C, Sequeira W (2014) Serum free light chains, interferon-alpha, and interleukins in systemic lupus erythematosus. Lupus 23:881–888
16. Jones RB (2014) Rituximab in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis. Nephron Clin Pract 128:243–249
17. Kormelink TG, Tekstra J, Thurlings RM, Boumans MH, Vos K, Tak PP, Bijlsma JW, Lafeber FP, Redegeld FA, van Roon JA (2010) Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity. Ann Rheum Dis 69:2137–2144
18. Lopez-Olivo MA, Amezaga Urruela M, McGahan L, Pollono EN, Suarez-Almazor ME (2015) Rituximab for rheumatoid arthritis. Cochrane Database Syst Rev 1:Cd007356
19. Nakano T, Nagata A, Takahashi H (2004) Ratio of urinary free immunoglobulin light chain kappa to lambda in the diagnosis of Bence Jones proteinuria. Clin Chem Lab Med 42:429–434
20. Segal R, Yaron M, Tartakovsky B (1990) Methotrexate: mechanism of action in rheumatoid arthritis. Semin Arthritis Rheum 20:190–200
21. Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A (2002) Ankylosing spondylitis: an overview. Ann Rheum Dis 61(Suppl 3):iii8–ii18
22. Stokes MB, Valeri AM, Herlitz L, Khan AM, Siegel DS, Markowitz GS, D’Agati VD (2015) Light chain proximal tubulopathy: clinical and pathologic characteristics in the modern treatment era. J Am Soc Nephrol
23. van Gestel AM, Prevoo ML, van ‘t Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 39:34–40
24. Waldmann TA, Strober W, Mogielnicki RP (1972) The renal handling of low molecular weight proteins. II. Disorders of serum protein catabolism in patients with tubular proteinuria, the nephrotic syndrome, or uremia. J Clin Invest 51:2162–2174
25. Zhang R, Li M, Chouhan KK, Simon EE, Hamm LL, Batuman V (2013) Urine free light chains as a novel biomarker of acute kidney allograft injury. Clin Transpl 27:953–960